Publications by authors named "Adrian Cook"

Claim this Profile
S
Sublobar resection or lobectomy for stage Ia non-small cell lung cancer: a systematic review and meta-analysis.
Lauren Kari Dixon, Ella Barber, Adrian Cook, Joanne Boudour, John Conibear

BMJ Open Respir Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.
Pauline Corbaux, Benoit You, Tatsuo Kagimura, Rosalind M Glasspool, Iain McNeish, Adrian Cook

Int J Gynecol Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.
Sarah Burdett, David J Fisher, Jayne F Tierney, Adrian D Cook, Daniel E Spratt

Eur Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England.
Joanna Dodkins, Adrian Cook, Emily Mayne, Marina Parry, Matthew G Parry

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation.
Joanna Dodkins, Adrian Cook, Emily Mayne, Marina Parry, Julie Nossiter

BMJ Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047).
Chris C Parker, Noel W Clarke, Adrian D Cook, Peter M Petersen, Charles N Catton

Eur Urol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is Centralisation of Cancer Services Associated With Under-Treatment of Patients With High-Risk Prostate Cancer?-A National Population-Based Study.
Lu Han, Emily Mayne, Joanna Dodkins, Richard Sullivan, Adrian Cook

Cancer Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Chris C Parker, Howard Kynaston, Adrian D Cook, Noel W Clarke, Charles N Catton

Lancet· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Chris C Parker, Noel W Clarke, Adrian D Cook, Howard Kynaston, Charles N Catton

Lancet· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review.
Joanna Dodkins, Julie Nossiter, Adrian Cook, Heather Payne, Noel Clarke

Eur Urol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What can patient-reported experience measures tell us about the variation in patients' experience of prostate cancer care? A cross-sectional study using survey data from the National Prostate Cancer Audit in England.
Melanie Morris, Adrian Cook, Joanna Dodkins, Derek Price, Steve Waller

BMJ Open· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial.
Peter Meidahl Petersen, Adrian D Cook, Matthew R Sydes, Noel Clarke, William Cross

Int J Radiat Oncol Biol Phys· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organisation and delivery of supportive services for patients with prostate cancer in the National Health Service in England and Wales: a national cross-sectional hospital survey and latent class analysis.
Joanna Dodkins, Adrian Cook, Melanie Morris, Julie Nossiter, Steve Prust

BMJ Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Pauline Corbaux, Benoit You, Rosalind M Glasspool, Nozomu Yanaihara, Anna V Tinker, Adrian Cook

Eur J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Adrian Cook

Lancet Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
Olivier Colomban, Andrew Clamp, Adrian Cook, Iain A McNeish, Benoit You

JCO Clin Cancer Inform· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Nicholas D James, Noel W Clarke, Adrian Cook, Adnan Ali, Alex P Hoyle

Int J Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
Benoit You, Lilian Van Wagensveld, Michel Tod, Gabe S Sonke, Hugo M Horlings, Adrian Cook

Br J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Andrew R Clamp, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Won Kim, Adrian D Cook

Lancet Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Chris C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Adnan Ali, Adrian Cook

PLoS Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Hannah L Rush, Laura Murphy, Alicia K Morgans, Noel W Clarke, Adrian D Cook

J Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Natalie Yl Ngoi, Nicholas Lx Syn, Robby M Goh, Boon Cher Goh, Ruby Yun-Ju Huang, Adrian Cook

Cochrane Database Syst Rev· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Gerhardt Attard, Laura Murphy, Noel W Clarke, William Cross, Robert J Jones, Adrian Cook

Lancet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Adnan Ali, Alex Hoyle, Áine M Haran, Christopher D Brawley, Adrian Cook

JAMA Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Robert D Morgan, Iain A McNeish, Adrian D Cook, Elizabeth C James, Rosemary Lord

Lancet Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis